CytoDyn CEO Talks Turkey.

SANTA FE, N.M. -- The Wall Street Reporter has begun streaming an interview with Allen D. Allen, CEO of CytoDyn, Inc. (OTCBB:CYDY). The host is Senior Analyst Ian Roberts. In his candid and didactic comments, Allen emphasizes the importance of basing drug development on science that has been established in the peer-review literature by a variety of independent researchers. Allen also explains the difference between immunologically mediated infectious diseases such as Lyme arthritis, and classical infectious diseases such as the flu and rabies. Unlike HIV and other germs that only cause disease in humans, the viruses responsible for the classical infectious diseases produce disease in any organism susceptible to the infection (an empirical proof of infection used by Koch to identify tuberculosis as an infectious disease). According to Allen, this distinction is key to moving targeted immune therapies beyond cancer and autoimmune diseases to treat infectious diseases.

During his interview on the Wall Street Reporter, Allen also elaborates on his short and long-term visions for CytoDyn, tries to blame his head cold on the smog in Los Angeles, and concludes by wishing you all a warm and joyful Holiday Season.